Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Werewolf Therapeutics Inc (NQ: HOWL ) 2.220 -0.060 (-2.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 246,211 Open 2.290 Bid (Size) 2.190 (4) Ask (Size) 2.330 (3) Prev. Close 2.280 Today's Range 2.190 - 2.400 52wk Range 1.573 - 8.194 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024 August 08, 2024 HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Performance YTD -52.16% -52.16% 1 Month -9.39% -9.39% 3 Month -58.58% -58.58% 6 Month -67.92% -67.92% 1 Year -19.57% -19.57% More News Read More Where Werewolf Therapeutics Stands With Analysts June 26, 2024 Via Benzinga Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma June 25, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session June 03, 2024 Via Benzinga Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know May 24, 2024 Via Benzinga The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts May 06, 2024 Via Benzinga Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors June 01, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference May 30, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting May 23, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Recap: Werewolf Therapeutics Q4 Earnings March 07, 2024 Via Benzinga HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 03, 2024 Via InvestorPlace Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 03, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting April 23, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting April 05, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting April 04, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023 March 07, 2024 Via InvestorPlace Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference March 06, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 March 05, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook January 08, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors January 04, 2024 From Werewolf Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session January 04, 2024 Via Benzinga Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference November 22, 2023 From Werewolf Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
